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Highlights
• Because biomedical scent detection is a potential tool to identify diseases, in the eyes of regulatory bodies it is comparable to a health technology.
• This is the ;rst report evaluating the canines' sense of smell from the point of view of a health technology.
• It is important for researchers to be aware of the required regulatory controls before dogs can have an accredited role in the clinic.
• We discuss the current advantages and disadvantages of the method to help guide researchers towards a<ainable goals.
INTRODUCTION
Canines' sense of smell has been utilized successfully for a long time for di:erent purposes, such as detection of explosives, narcotics, and bed bugs, to name just a few. Biomedical scent detection (or medical scent detection) is an emerging method that uses the canine olfactory capacity for identifying the scent pro;les of diseases, such as di:erent types of cancers (Moser and McCulloch 2010; Jezierski et al. 2015) , diabetes (Gadbois and Reeve 2014; Hardin et al. 2015) or the presence of pathogenic micro-organisms (Bomers et al. 2014; Bryce et al. 2017; Koivusalo et al. 2017; Koskinen et al. 2017) . It is the combination of the acuity of the sense of smell with the ability to learn by operant conditioning that makes dogs potential biodetectors for di:erent tasks (Pirrone and Albertini 2017) . The ultimate goal in most cases is to involve dogs as a fast method for the diagnosis or screening of human patient disease. Research studies illustrate that dogs are capable of distinguishing the volatile organic compounds characteristic of diseases (Rudnicka et al. 2014 ). An important topic to take into consideration when training and testing dogs for this purpose is a comparison with conventional technologies used in screening and diagnosis. If a dog's indication is to be used in making decisions on a patient's health and treatment outcomes, canine scent detection would be comparable to a health technology in the eyes of health organizations and regulatory bodies. The purpose of this review it to evaluate canine scent detection as a medical device, to assess whether it would pass a health technology assessment (HTA) as it currently stands and what the most pertinent technical challenges are.
DEFINITION AND QUALITY ASSESSMENT OF HEALTH TECHNOLOGIES
The The aspects to be evaluated depend on the technology in question and the assessing regulatory body. The following information, which is pertinent also to biomedical scent detection, is always asked:
• Description of the health problem and currently available technology for solving it.
• Technical description of the new technology in detail.
• Clinical e:ectiveness: Does the new technology work equally well or be<er than a standard method currently in use? The requirement before granting a permission for marketing is to demonstrate that the technology is at least "substantially equivalent" (FDA) to a current standard technology.
• Safety: The technology has to be safe not only for the patients but also for the people operating it. Potential risks and harms are assessed that will determine the risk classi;cation of the technology.
• Economic evaluation:
Value-for-money assessment is conducted to evaluate the costs and bene;ts of the technology in relation to health-related outcomes as well as the economic burden on the healthcare system and society.
• Ethical, social, organizational and legal aspects may also be evaluated.
HOW DOES BIOMEDICAL SCENT DETECTION RANK IN EVALUATION OF THE MOST FUNDAMENTAL CRITERIA?

CLINICAL EFFECTIVENESS
If we ask whether dogs can smell cancer or a pathogen, the answer would be a 'yes', as dogs can detect diseases with very high levels of sensitivity and speci;city (Jezierski et al. 2015) . But to assess the clinical e:ectiveness of the technology the question is: can dogs do it with the same reproducibility and accuracy as an analytical instrument already in use, and can patient treatment outcomes be planned on the basis of the results?
To be approved by health organizations, several aspects need to be addressed before the answer is 'yes' for canine scent detection (Fig. 1) .
Here are some of the main challenges that scent detection researchers are trying to solve:
1) Standardization of the Training and Testing Methods
Currently there is no standardized way to train and test the dogs, which leads to variability in results (as discussed by Elliker et al. 2014; Jezierski et al. 2015; Gadbois & Reeve, 2016) . Traditionally dogs have been trained and tested using an alternative forced choice (AFC) method, where a line-up or a scent wheel contains one target scent (S+, here, a "disease odour") and several non-target or distractor scents (S-, a healthy control odour), and then running double-blind trials, where neither the dog nor the dog handler knows the sample positioning and the dog is required to locate and indicate the target, diseased, odour. This method is appropriate for a proof-of-principle study, but in a real screening situation the number of S+ and S-samples is unknown. If the dog has been trained to always ;nd one 'win' in a line-up, what happens in a screening situation?
Studies have shown that when dogs were trained using the AFC task of one S+ and four S-samples, and then tested with randomized numbers of S+ and S-samples, the sensitivity and speci;city of their performance deteriorated signi;cantly (Amundsen et al. 2014; Hackner et al. 2016) . This illustrates the importance of training and testing the dogs with randomized samples The AFC method also has a disadvantage due to a memory load it may impose on the detection dog. Gadbois and Reeve (Gadbois and Reeve 2014; have shown that the accuracy of canines decreases signi;cantly the further down the target is in the lineup because of a tax on the dogs' memory processing. The goal of biomedical scent detection is to assess the sensory-perceptual abilities of dogs to distinguish scents extremely similar to each other, and not make the process a memory load task of a past event. Therefore, to avoid the tax on memory, the use of discrimination tasks of 2 or 3 choices is more favourable (Gadbois and Reeve 2014; Koivusalo et al. 2017 ). An even more elegant solution is a pure detection task, i.e. a yes/no, go/no-go system, where the dog is presented with one stimulus at a time, which requires a 'yes' or 'no' answer Reeve 2014, 2016) . In this approach the dog always gets a win and the task is a pure sensory task, which increases accuracy.
2) Reproducibility
An analytical laboratory instrument analyzes hundreds of samples daily with high accuracy and throughput, albeit a certain degree of variability (as discussed by Moser & McCulloch 2010) . Dogs cannot be considered as instruments, and they will never obtain an accuracy of 100% due to their own inherent variability (Hackner and Pleil 2017) . Furthermore, the published medical scent detection studies are di:erent from real screening situations, where larger sets of samples would be processed daily, and the reproducibility will be harder to accomplish. This stems from several factors:
The work of an 'analytical' dog is highly repetitive, and it can be diIcult to keep up their motivation, as dogs are subject to boredom, fatigue and external distractions. The job of these dogs is di:erent from the scent detection work in the ;eld (e.g. drugs, explosives, search and rescue), where the dogs get to use more of their natural 'hunting' behaviors and the task remains more of a game to them.
In contrast to laboratory devices, dogs may try and change their strategies in order to be rewarded at minimum e:ort leading to inaccuracies during doubleblind trials.
The handler's positive and negative sensations are easily transmi<ed to the dogs. Also, in contrast to analytical devices that detect compounds very speci;cally, each individual dog can perceive complex scent pa<erns di:erently leading to variability between di:erent dogs. Finding dogs with an ability to generalize the complex detection task is important.
3) Detection of Diseases in True Unknown Samples
Most published studies have been performed with samples from already diagnosed patients. However, it is crucial to improve the overall survival: earlier cancer detection may permit earlier intervention and detection of colonization by a pathogen prior to an actual infection may enable early treatment and containment as well. Therefore, the next step aTer standardization of training/testing methods is to obtain results with completely unknown samples.
It is likely that the scent pro;le changes between samples from patients with an advanced vs. an earlier stage of disease. Amundsen et al. (Amundsen et al. 2014) showed that the dogs' performance is a:ected when they are tested with patients suspected to have di:erent stages and forms of lung cancer. This ;nding highlights the importance of training the dogs not only with samples from patients with an advanced or malignant disease but with samples from benign stages of disorders.
To teach the dogs the subtle discrimination among di:erent stages of a disease may not be a trivial task, as what truly is a positive sample and what is a negative one can turn out to be a grey area. This is where drawing realistic cut-o:s for what dogs can and cannot do should be considered.
4) Sample presentation
One experimental factor to consider and standardize is the way the biological samples are presented and preserved (Hackner and Pleil 2017; Reeve et al. 2017) .
Also the protocol used (or not used) to clean and handle the scent containers between trials di:ers widely, but ultimately the goal is that the dogs discriminate the target scent amongst any background scent. What is important to acknowledge in biomedical scent detection is that the dog is constantly learning to discriminate subtle di:erences between samples, and without due diligence they may accidentally learn to indicate something superUuous or superstitious. To circumvent this, many researchers se<le for a set cleaning protocol or using disposable scent containers only (Jezierski et al. 2015; Koivusalo et al. 2017; Koskinen et al. 2017) .
SAFETY
This is one of most a<ractive qualities of biomedical scent detection: it is very non-invasive in nature, and therefore safe for the patients. For some patients a physical interaction with animals may be a concern, but if the detection work takes place in a laboratory, there is no need for contact between the patients and the dogs.
An important risk assessment to be made is the evaluation of the consequences of false positive (dog indicates an S-sample) and false negative (dog does not indicate S+) results. False negative results would impose a more serious safety concern, as it would involve missing patients at risk.
COST EVALUATION
Another appealing quality of biomedical scent detection is its potential to be more cost-e:ective than many expensive laboratory methods. For example, Arnaud (2016) determined that biopsy-based methods of non-small cell lung cancer biomarker testing can cost upwards of $2,500. The analysis of volatile organic compounds (VOCs, Amann et al. 2014) in exhaled breath samples is a much less expensive, and less invasive procedure, and has proven a promising avenue for cancer diagnosis (Shirasu and Touhara, 2011) . The analytical techniques used to identify disease-speci;c VOCs, such as SPME and GC-MS, however, can be expensive and extensive training is required to perform the analysis and analyze the results (Shirasu and Touhara, 2011) . Alternatively, the identi;cation of diseased breath samples by detection dogs requires minimal equipment and the analysis (interpretation of the dogs' indication behaviour), is straight forward (Jezierski et al. 2015) . McCulloch et al. (2006) examined canine detection of non-small cell lung cancer in donated breath samples and showed that the dogs were 99% sensitive and speci;c, providing evidence for a highly promising yet cheaper detection system. Also, dogs would be a rational solution in areas where high-tech instrumentbased analysis is unavailable (Rooney et al. 2013; Jezierski et al. 2015) The disadvantage is that the process of training a dog is a time-consuming and hence a money-consuming process because it can take up to a year to train a dog; fully trained medical alert dogs can cost anywhere between $8000 -$20,000 USD (beyondtype1.org). Even then, it does not mean that every individual dog is suitable for the task, and even at later stages of testing, some dogs may not show the desired sensitivity and speci;city (Jezierski et al. 2015) .
CONCLUSION
To be approved as a clinically valid health technology by regulatory bodies, biomedical scent detection has not reached the required standard yet. Whether it will, depends on the crucial research that needs to be done. In the current age of high-tech medical devices competing in the market, se<ing a realistic target for the canines might speed up the process as it is a race of who has the most clinically e:ective and cost-e:ective method ;rst. In order to make biomedical scent detection a reliable health technology, understanding of the canine olfactory learning processes is needed both through a clinical research and psychophysical approach.
